Results 1 to 10 of about 17,859 (212)

Pharmacometric‐Based Evaluation of Salmeterol and Its Metabolite α‐Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Salmeterol is a commonly used β2‐agonist included on the List of Prohibited Substances and Methods published by the World Anti‐Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its ...
Paul Thoueille, Anne Danion, Morten Hostrup, Michael Petrou, Koen Deventer, Thierry Buclin, François R. Girardin, Irene Mazzoni, Olivier Rabin, Monia Guidi   +9 more
doaj   +3 more sources

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study [PDF]

BMC Pulmonary Medicine, 2011
Background The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform®) in a single ...
McAulay Kirsten, Dymek Andrzej, Bodzenta-Lukaszyk Anna, Mansikka Heikki   +3 more
doaj   +4 more sources

Salmeterol

Reactions Weekly, 2006
europepmc   +4 more sources

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Molecules, 2022
The rational preparation of molecularly imprinted polymers (MIPs) in order to have selective extraction of salmeterol xinafoate (SLX) from serum was studied.
Shendi Suryana, Mutakin Mutakin, Yudi Rosandi, Aliya Nur Hasanah   +3 more
doaj   +1 more source

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids

BMC Infectious Diseases, 2020
Objectives To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone/salmeterol or budesonide/formoterol, and to identify any differences between these two groups of patients.
Tsan-Ming Huang, Kuan-Chih Kuo, Ya-Hui Wang, Cheng-Yi Wang, Chih-Cheng Lai, Hao-Chien Wang, Likwang Chen, Chong-Jen Yu, On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)   +8 more
doaj   +1 more source

Tailored second line therapy in asthmatic children with the arginine-16 genotype [PDF]

, 2012
The arginine-16 beta-2 receptor genotype confers increased susceptibility to exacerbations in asthmatic children taking regular long acting beta-2 agonists.
Aziz, Basu, Bateman, Bleecker, Brian J. Lipworth, British Thoracic Society, Colin N. A. Palmer, Currie, Donald F. Macgregor, Drysdale, Fuhlbrigge, Hall, Helen P. Donald, Joos, Juniper, Kaninika Basu, Kramer, Lee, Lemanske, Liggett, Lipworth, Martinez, Palmer, Roger Tavendale, Simon A. Ogston, Somnath Mukhopadhyay, Wechsler, Wilson   +27 more
core   +1 more source

Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease

Respiratory Research, 2010
Background The relationship between airway structural changes (remodeling) and airways hyperresponsiveness (AHR) is unclear. Asthma guidelines suggest treating persistent asthma with inhaled corticosteroids and long acting β-agonists (LABA).
Lundblad Lennart K, Haverkamp Hans C, Thompson-Figueroa John A, Sullivan Michael J, Riesenfeld Erik P, Bates Jason HT, Irvin Charles G   +6 more
doaj   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers, Aalbers, Altman, Barnes, Beach, Bleecker, Busse, Cates, Cates, Cates, Cates, Cates, Dahl, Ducharme, Ducharme, Ducharme, Giembycz, Higgins, Lasserson, Lipworth, Nelson, Ni Chroinin, Papi, Ringdal, Salpeter, Tamminen, Walters, Walters   +27 more
core   +2 more sources

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]

, 2012
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Altman, Blauw, Cates, Cates, Cates, Cates, Cates, Ducharme, Giembycz, Greenstone, Lipworth, Nelson, Ni Chroinin, Ni Chroinin, Pearce, Salpeter, Sears, Walters, Walters   +18 more
core   +1 more source

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study) [PDF]

, 2016
Background: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment
Beeh, Kai-Michael, Bjermer, Leif,, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Lund University., Lund University., Zhai, Dongmei   +8 more
core   +2 more sources